Lithium Hydroxide → 9-Bromo-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepine-2-carboxylic acid

HRID 886538Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 886538
[Br:1][C:2]1[CH:19]=[CH:18][C:5]2[C:6]3[N:7]([CH:11]=[C:12]([C:14]([O:16]C)=[O:15])[N:13]=3)[CH2:8][CH2:9][O:10][C:4]=2[CH:3]=1.[Li+].[OH-]>C1COCC1.O>[Br:1][C:2]1[CH:19]=[CH:18][C:5]2[C:6]3[N:7]([CH:11]=[C:12]([C:14]([OH:16])=[O:15])[N:13]=3)[CH2:8][CH2:9][O:10][C:4]=2[CH:3]=1

Komponenten

4

Edukt 2

HCID 3939Lithium HydroxideHCID 58204541Methyl 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylate

Produkt 1

HCID 582043519-Bromo-5,6-dihydrobenzo[F]imidazo[1,2-D][1,4]oxazepine-2-carboxylic acidAusbeute 90,5 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 21881883Oxolane--water (1/1)Lösungsmittel

Reaktionsbedingungen

Temperatur
70 °C

Versuchsvorschrift

methyl 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxylate (3.5 g, 10.8 mmol) and LiOH (0.52 g, 21.7 mmol) were dissolved in a mixture of THF:H2O (1:1, 150 mL). After the resulting mixture was stirred at 70° C. for 2 h, the water phase of the reaction mixture was separated, adjusted to pH 4.0 and extracted with EtOAc (100 mL×4). The organic phase was pooled and concentrated to give product (3.0 g, 90.5%). LCMS (ESI): m/z 310.6 (M+H+)

Aufarbeitung

  1. customthe water phase of the reaction mixture was separated
  2. extractionextracted with EtOAc (100 mL×4)
  3. concentrationconcentrated

Quellen und Nachweise

ORD-Eintrag
ord-e520de062a934c2486ca5af5bfb08e83
Quelldatensatz
uspto-grants-2012_08
Patentnummer
US08242104B2

Notizen zur Reaktion

Wird geladen…